SPOTLIGHT -
Stay away from one-size-fits-all treatments for pediatric respiratory infections
A new study notes that coinfections, amongst other issues, can complicate diagnosis and management of respiratory infections in children.
Food Insecurity and the Dangers of Infant Formula Dilution
Children conceived in winter and spring had increased risk of cerebral palsy
An increased risk of cerebral palsy was observed in children conceived in the winter and spring compared to summer, according to a recent study published in JAMA Network Open.
Demystifying Infant Formula
Will FDA approved phentolamine ophthalmic solution 0.75% eye drops impact pediatric care?
In this Contemporary Pediatrics® interview, Rupa Wong, MD, discusses the recent FDA approval of phentolamine ophthalmic solution 0.75% eye drops to treat pharmacologically-induced mydriasis, and how this could impact the treatment landscape for the pediatric population. [Editor's note: RYZUMVI was previously known as Nyxol, which is referenced in the interview.]
FDA approves phentolamine ophthalmic solution 0.75% eye drops for pharmacologically-induced mydriasis
Results from the phase 3 MIRA-4 pediatric trial demonstrated a favorable safety and tolerability profile with no reported adverse events. Rupa Wong, MD, offers thoughts on the approval, and why it may not change day-to-day practice when it comes to the pediatric population.
